We are pleased to announce that our Fund has recently added Raidium, a seed-stage company specializing in precision radiology, to our portfolio.
Raidium is pioneering the development of a radiological multimodal foundation model, often referred to as the “GPT of radiology.” This advanced AI-native platform integrates seamlessly into radiologists’ workflows, providing interactive AI assistance through multimodal prompting, including text, images, and voice. By being modality-invariant and capable of whole-body imaging in 3D, Raidium’s platform enhances diagnostic accuracy and efficiency across various medical imaging modalities.
Another feature of Raidium’s platform is an AI-biomarker API that revolutionizes clinical trials by enabling scalable cohort-level analysis of imaging biomarkers. This tool not only improves existing biomarkers but also facilitates the development of new ones tailored to emerging treatments, significantly enhancing efficiency in clinical research. By collaborating with the pharmaceutical industry, Raidium leverages these AI-driven biomarkers to streamline drug development, from early identification to optimizing clinical trials, ensuring that new therapies reach the market faster and more effectively.
We were impressed by Raidium’s innovative approach,connecting research and routine care by speeding up the adoption of biomarkers and using AI-native radiology tools for research. Their ambition to develop large multimodal models — integrating text and diverse medical imaging across all organs — is very innovative and promising. Their AI solutions not only enhance existing biomarker automation but also reduce measurement variability, delivering significant value for both researchers and patients.
– Vincent Lepreux, Investment Director at Debiopharm Innovation Fund.
Our ambition is to make foundation models productive for radiologists, to fully leverage ubiquitous medical imaging in new innovative biomarkers and bring them to the patients. This large seed round will bolster our growth and let us support many more industrial as well as academic biomarker research projects. We’ll deploy the product we’ve prototyped to market and continue growing our world-class team.
– Dr. Paul Herent CEO and co-founder of Raidium.